share_log

BTIG Maintains Buy on Pear Therapeutics, Lowers Price Target to $5

BTIG Maintains Buy on Pear Therapeutics, Lowers Price Target to $5

BTIG 維持對Pear Therapeutics的買入,將目標價下調至
Benzinga Real-time News ·  2022/08/12 21:52

BTIG analyst Marie Thibault maintains Pear Therapeutics (NASDAQ:PEAR) with a Buy and lowers the price target from $11 to $5.

BTIG分析師瑪麗·蒂博維持Pear Therapeutics(納斯達克股票代碼:PEAR)的買入,並將目標股價從11美元下調至5美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論